natgillin/translations-raw huggingface dataset:
Do not take FOSAVANCE (1) if you are allergic (hypersensitive) to alendronate sodium trihydrate, colecalciferol or any of the other ingredients, (2) if you have certain problems with your gullet (oesophagus - the tube that connects your mouth, with your stomach) such as narrowing or difficulty swallowing, (3) if you cannot stand or sit upright for at least 30 minutes, (4) if your doctor has told you that you have low blood calcium.
(1) če ste alergični na (preobčutljivi za) natrijev alendronat trihidrat, holekalciferol ali katerokoli drugo sestavino, (2) če imate težave s požiralnikom (del prebavne cevi med žrelom in želodcem) kot je zoženo ali oteženo požiranje, (3) če ne morete stati ali pokončno sedeti vsaj 30 minut, (4) če vam je zdravnik povedal, da imate nizko vrednost kalcija v krvi.
47 Children and adolescents FOSAVANCE should not be given to children and adolescents.
47 Otroci in mladostniki Zdravila FOSAVANCE se ne sme dajati otrokom ali mladostnikom.
Every week, take one FOSAVANCE tablet on your chosen day.
Potem ko zjutraj vstanete in še preden zaužijete prvo hrano, pijačo ali katerokoli drugo zdravilo, pogoltnite tableto FOSAVANCE samo s polnim kozarcem vode (ne mineralne vode) (in ne manj kot 200 ml).
It is very important to follow instructions 2), 3), 4) and 5) to help the FOSAVANCE tablet reach your stomach quickly and help reduce the chance of irritating your gullet (oesophagus - the tube that connects your mouth with your stomach).
- Ne vzemite z mineralno vodo (z mehurčki ali brez).
2) After getting up for the day and before taking any food, drink, or other medicine, swallow your FOSAVANCE tablet with a full glass of water only (not mineral water) (not less than 200 ml or 7 fl. oz.). • Do not take with mineral water (still or sparkling). • Do not take with coffee or tea. • Do not take with juice or milk.
- Ne vzemite s kavo ali čajem.
48 4) Do not take FOSAVANCE at bedtime or before getting up for the day.
Zdravila FOSAVANCE ne jemljite zvečer ali preden zjutraj vstanete.
49 • narrowing of the gullet (oesophagus – the tube that connects your mouth with your stomach), • blurred vision, pain or redness in the eye, • rash made worse by sunlight, • severe bone, muscle and/ or joint pain, • mouth ulcers when the tablets have been chewed or sucked, • transient flu-like symptoms, such as aching muscles, generally feeling unwell and sometimes with fever usually at the start of treatment.
49 Redki: • alergijske reakcije, kot npr. koprivnica, oteklina obraza, ustnic, jezika in/ ali žrela, ki lahko otežuje dihanje ali požiranje • simptomi nizke ravni kalcija v krvi, vključno z mišičnimi krči ali spazmom in/ ali mravljinčenjem v prstih ali okrog ust • razjede v ustih ali peptične razjede (včasih hude ali s krvavitvijo) • zožitev požiralnika • zamegljen vid, bolečina v očesu, rdeče oko • izpuščaj, ki se poslabša na soncu • hude bolečine v kosteh, mišicah in/ ali sklepih • razjede v ustih pri sesanju ali žvečenju tablete • prehodni gripi podobni simptomi, kot npr. bolečine v mišicah, splošno slabo počutje in včasih z zvišano telesno temperaturo, običajno ob začetku zdravljenja
The other ingredients are microcrystalline cellulose (E460), lactose anhydrous, medium chain triglycerides, gelatin, croscarmellose sodium, sucrose, colloidal silicon dioxide, magnesium stearate (E572) butylated hydroxytoluene (E321), modified starch (maize), and sodium aluminium silicate (E554).
50 Pomožne snovi so mikrokristalna celuloza (E460), brezvodna laktoza, srednjeverižni trigliceridi, želatina, premrežen natrijev karmelozat, saharoza, koloidni silicijev dioksid, magnezijev stearat (E572), butilhidroksitoluen (E321), modificirani škrob (koruzni) in natrijev aluminijev silikat (E554)
50 What FOSAVANCE looks like and contents of the pack
Izgled zdravila FOSAVANCE in vsebina pakiranja
FOSAVANCE 70 mg/ 5600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘ 270’ on the other.
FOSAVANCE 70 mg/ 5. 600 i. e. tablete so pravokotniku podobne oblike, bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘ 270 ’.
51 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@msd. de
51 Deutschland MSD SHARP & DOHME GMBH Tel: +49 (0) 89 4561 2612 Infocenter@ msd. de
52 Lietuva UAB “ Merck Sharp & Dohme” Tel.: +370 5 278 02 47 msd_lietuva@merck. com
52 Lietuva UAB “ Merck Sharp & Dohme ” Tel.: +370 5 278 02 47 msd_ lietuva@ merck. com
Foscan is a solution for injection containing the active substance temoporfin (1 or 4 mg/ ml).
Zdravilo Foscan je raztopina za injiciranje, ki vsebuje zdravilno učinkovino temoporfin (1 ali 4 mg/ ml).
It is used in patients in whom other treatments have stopped working, and who are not suitable for radiotherapy (treatment with radiation), surgery or systemic chemotherapy (medicines used to treat cancer; ‘ systemic ’ means that they are given as treatments throughout the body).
Uporablja se pri bolnikih, pri katerih so druga zdravila prenehala učinkovati in ki niso primerni za radioterapijo (zdravljenje z obsevanjem), operacijo ali sistemsko kemoterapijo (zdravila za zdravljenje raka; „ sistemska “ pomeni, da zdravila delujejo po celem telesu).
Foscan must only be given in a specialist cancer centre where a team can assess the patient’ s treatment under the supervision of a doctor who has experience in photodynamic therapy (treatment that uses light).
Zdravilo Foscan se sme dajati samo v specialističnih onkoloških centrih, kjer lahko ekipa spremlja bolnikovo zdravljenje pod nadzorom zdravnika, ki ima izkušnje s fotodinamičnim zdravljenjem (zdravljenjem, pri katerem se uporablja svetloba).
Treatment with Foscan is a two-step process: the medicine is given first, before it is activated using a laser.
Zdravljenje z zdravilom Foscan poteka v dveh korakih: najprej se zdravilo injicira, nato pa se ga aktivira z laserjem.
The medicine is given by an indwelling intravenous cannula (a thin tube permanently inserted into a vein) as a single slow injection over at least six minutes.
Zdravilo se aplicira skozi stalno vensko kanilo (tanko cevko, ki je stalno vstavljena v veno) z enkratnim počasnim injiciranjem, ki mora trajati vsaj šest minut.
The dose is 0.15 mg per kilogram body weight.
Odmerek je 0, 15 mg na kilogram telesne mase.
Four days later, the entire surface of the tumour and the surrounding 0.5-cm margin is illuminated with light from a laser at a specific wavelength, using a fibre-optic cable, for around three minutes and 20 seconds.
Štiri dni pozneje je treba celotno površino tumorja in območje 0, 5 cm okoli roba tumorja osvetljevati s svetlobo specifične valovne dolžine iz laserskega vira prek kabla iz optičnih vlaken približno tri minute in 20 sekund.
Each area of the tumour should be illuminated only once during each treatment.
Vsako območje tumorja se lahko med vsakim ciklusom zdravljenja osvetli samo enkrat.
If a second treatment is necessary, this should take place at least four weeks later.
Če je potrebno ponovno zdravljenje, se mora to izvesti vsaj štiri tedne pozneje.
When Foscan is injected, temoporfin is distributed within the body, including within the tumour.
Ko zdravilo Foscan injiciramo, se temoporfin porazdeli po celem telesu, vključno v tumorju.
By restricting the illumination to the tumour, cell damage is limited to the tumour cells, leaving other areas of the body unaffected.
Ta ubije celice tako, da reagira z njihovimi komponentami, na primer z njihovimi
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. beljakovinami in DNK, in te komponente uniči.
Foscan has been studied in four main studies involving a total of 409 patients with head or neck cancer.
Zdravilo Foscan so preučevali v štirih glavnih študijah s skupno 409 bolniki z rakom glave ali vratu.
The first three studies looked at whether the tumour was eradicated after up to three treatments with Foscan in a total of 189 patients.
V prvih treh študijah so pri skupno 189 bolnikih preučevali, ali je bil tumor po največ treh ciklusih zdravljenja z zdravilom Foscan uničen.
The fourth study looked at the reduction of symptoms in 220 patients with advanced head or neck cancer who could not receive surgery or radiotherapy.
V četrti študiji so preučevali zmanjšanje simptomov pri 220 bolnikih z napredovalim rakom glave ali vratu, ki niso bili primerni za operacijo ali obsevanje.
However, in the study looking at improving symptoms of advanced head and neck cancer, 28 (22%) of the 128 patients assessed had a significant improvement in their most troubling symptom.
Vendar pa je v študiji, v kateri so preučevali izboljšanje simptomov napredovalega raka glave in vratu, 28 (22%) izmed 128 obravnavanih bolnikov izkazalo pomembno izboljšanje najhujšega simptoma.
The most common side effects with Foscan (seen in more than 1 patient in 10) are pain at the injection site, at the site of the tumour or in the face, haemorrhage (bleeding), scarring, mouth necrosis (death of cells or tissue in the mouth), dysphagia (difficulty swallowing), face oedema (swelling) and constipation.
Najpogostejši neželeni učinki zdravila Foscan (opaženi pri več kot 1 bolniku izmed 10) so bolečina na mestu injiciranja, na mestu tumorja ali na obrazu, krvavitve, brazgotine, nekroza ust (odmiranje celic ali tkiva v ustih), disfagija (težave pri požiranju), obrazni edem (oteklina) in zaprtje.
For the full list of all side effects reported with Foscan, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Foscan, glejte navodilo za uporabo.
Foscan should not be used in people who may be hypersensitive (allergic) to temoporfin or any of the other ingredients.
Zdravila Foscan ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) temoporfin ali katero koli drugo sestavino zdravila.
Foscan must not be used in patients with porphyria (an inability to break down porphyrins), other diseases made worse by light, allergy to porphyrins, or tumours that are spreading into a blood vessel or that are next to where the laser is to be shone.
Zdravila Foscan ne smejo uporabljati bolniki s porfirijo (nezmožnostjo razgradnje porfirinov), drugimi boleznimi, ki jih svetloba poslabša, alergijo na porfirine ali tumorji, ki se širijo v krvne žile na ali v bližini mesta, osvetljevanega z laserjem.
Foscan must also not be used in patients who have an operation planned in the next 30 days, who have an eye disease that is likely to need examination using a ‘ slit lamp’ (an instrument used by eye specialists to look into the eye) in the next 30 days, or who are already being treated with another medicine that increases sensitivity to light.
Zdravila Foscan prav tako ne smejo uporabljati bolniki, pri katerih je v naslednjih 30 dneh načrtovana operacija, bolniki z očesno boleznijo, pri kateri bo v naslednjih 30 dneh verjetno potreben pregled s špranjsko svetilko (instrumentom, ki ga uporabljajo specialisti za oči za pregled očesa), ali bolniki, ki se že zdravijo z drugim zdravilom, ki povečuje občutljivost na svetlobo.
Patients receiving Foscan should take care to avoid exposure to bright light for up to six months after injection to avoid skin burns.
Bolniki, ki prejemajo zdravilo Foscan, se morajo šest mesecev po injiciranju izogibati izpostavljenosti močni svetlobi, sicer lahko pride do kožnih opeklin.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Foscan’ s effects on relieving the symptoms associated with advanced head and neck cancer were of interest.
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da ima zdravilo Foscan pozitivne učinke pri blaženju simptomov, povezanih z napredovalim rakom glave in vratu.
Therefore, the Committee decided that Foscan’ s benefits are greater than its risks for the palliative treatment of patients with advanced head and neck squamous cell carcinoma who have failed other treatments and are not suitable for radiotherapy, surgery or systemic chemotherapy.
Posledično je Odbor odločil, da so koristi zdravila Foscan pri paliativnem zdravljenju bolnikov z napredovalim ploščatoceličnim rakom glave in vratu, pri katerih druge oblike zdravljenja niso bile uspešne in ki niso primerni za obsevanje, operacijo ali sistemsko kemoterapijo, večje od z njim povezanih tveganj.
The Committee recommended that Foscan be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Foscan odobri dovoljenje za promet.
Foscan was originally authorised under ‘ Exceptional Circumstances’, because, as the disease is rare and for scientific reasons, limited information was available at the time of approval.
Zdravilo Foscan je bilo prvotno odobreno v „ izjemnih okoliščinah “, saj so bile zaradi redkosti bolezni in iz znanstvenih razlogov v času odobritve na voljo le omejene informacije.
As the company had supplied the additional information requested, the ‘ Exceptional Circumstances ’ ended on 21 May 2008.
Ker je družba predložila dodatne zahtevane informacije, so „ izjemne okoliščine “ prenehale veljati dne 21. maja 2008.
Other information about Foscan:
Druge informacije o zdravilu Foscan:
The marketing authorisation was renewed on 24 October 2006.
Dovoljenje za promet z zdravilom je bilo obnovljeno dne 24. oktobra 2006.
The marketing authorisation holder is Biolitec Pharma Ltd.
Imetnik dovoljenja za promet je družba Biolitec Pharma Ltd.
The full EPAR for Foscan can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Foscan je na voljo tukaj.
Pharmaceutical form Solution for injection Solution for injection Solution for injection Solution for injection Solution for injection
Za intravenozno uporabo.
Route of administration Intravenous use Intravenous use Intravenous use Intravenous use Intravenous use
Viala (temno obarvano steklo)
Packaging Vial (amber glass) Vial (amber glass) Vial (amber glass) Vial (amber glass) Vial (amber glass)
Viala (temno obarvano steklo)
Package size 1 vial 1 vial 1 vial 1 vial 1 vial
Viala (temno obarvano steklo)
Foscan 1 mg/ ml solution for injection
Foscan 1 mg/ ml raztopina za injiciranje
Excipients:
Pomoţne snovi:
Each ml contains 376 mg of ethanol anhydrous and 560 mg of propylene glycol
En ml vsebuje 376 mg brezvodnega etanola in 560 mg propilenglikola.
For a full list of excipients, see section 6.1
Za celoten seznam pomoţnih snovi glejte poglavje 6. 1.
Dark purple solution.
Temno vijolična raztopina.
Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.
Foscan je indiciran za paliativno zdravljenje bolnikov z napredovalim ploščatoceličnim rakom glave in vratu, pri katerih prejšnja zdravljenja niso bila uspešna in niso primerni za radioterapijo, kirurški poseg ali sistemsko kemoterapijo.
Foscan photodynamic therapy must only be administered in specialist oncology centres in which a multidisciplinary team assesses patient treatment and under the supervision of physicians experienced in photodynamic therapy.
Fotodinamično zdravljenje z zdravilom Foscan se lahko izvaja le v specialističnih onkoloških centrih, kjer multidisciplinarna ekipa določi zdravljenje bolnika, in pod nadzorom zdravnikov, ki ţe imajo izkušnje s fotodinamičnim zdravljenjem.
Foscan is administered via an in-dwelling intravenous cannula in a large proximal limb vein, preferably in the antecubital fossa, as a single slow intravenous injection over not less than 6 minutes.
Zdravilo Foscan apliciramo skozi stalno vensko kanilo v večjo proksimalno ţilo uda, po moţnosti v antekubitalni fosi z enkratnim počasnim intravenskim injiciranjem, ki ne sme trajati manj kot 6 minut.
The patency of the in-dwelling cannula should be tested before injection and every precaution taken against extravasation (see section 4.4).
Pred injiciranjem je treba preizkusiti prehodnost stalne kanile in paziti, da ne pride do ekstravazacije (glejte poglavje 4. 4).
Thus, an in-line filter must be used as a precautionary measure and is provided in the package.
Zato je potrebno kot varnostni ukrep uporabiti zaporedni filter, ki je priloţen v pakiranju.
Do not flush with sodium chloride or any other aqueous solution.
Ne izpirajte z natrijevim kloridom ali katero koli drugo vodno raztopino.
The dose is 0.15mg/ kg body weight.
Odmerek je 0, 15 mg/ kg telesne mase.
Do not dilute Foscan.
Zdravila Foscan ne redčite.
Administer the required dose of Foscan by slow intravenous injection, over not less than 6 minutes.
Ustrezen odmerek zdravila Foscan aplicirajte s počasnim intravenskim injiciranjem najmanj 6 minut.
96 hours after the administration of Foscan, the treatment site is to be illuminated with light at 652 nm from an approved laser source.
96 ur po aplikaciji zdravila Foscan mora biti zdravljeno mesto obsevano s predpisano lasersko svetlobo valovne dolţine 652 nm.
Wherever possible, the illuminated area must extend beyond the tumour margin by a distance of 0.5cm.
Obsevano območje mora obsegati, kjer je to le mogoče, tudi področje 0, 5 cm okoli roba tumorja.
Light must be administered not less than 90 hours and not more than 110 hours after Foscan injection.
Presledek med injekcijo Foscana in obsevanjem ne sme biti niti krajši od 90 ur niti daljši od 110 ur.
The incident light dose is 20J/ cm2, delivered at an irradiance of 100mW/ cm2 to the tumour surface, implying an illumination time of approximately 200 seconds.
Odmerek vpadne svetlobe je 20 J/ cm2 pri iradiaciji 100 mW/ cm2 na površino tumorja in pri času obsevanja pribliţno 200 sekund.
2 Each field is to be illuminated once only at each treatment.
2 Vsako polje mora biti pri posameznem zdravljenju obsevano le enkrat.
Use in children - There is no relevant indication for use of Foscan in children or adolescents.
Uporaba pri otrocih - Ustreznih indikacij za uporabo zdravila Foscan pri otrocih in mladostnikih ni.
 Hypersensitivity to the active substance or to any of the excipients.  Porphyria or other diseases exacerbated by light.  Hypersensitivity to porphyrins.  Tumours known to be eroding into a major blood vessel in or adjacent to the illumination site.  A planned surgical procedure within the next 30 days.  Coexisting ophthalmic disease likely to require slit-lamp examination within the next 30 days.  Existing therapy with a photosensitizing agent.
– porfirija ali druge bolezni, ki jih poslabša svetloba; – preobčutljivost za porfirine; – tumorji, ki razjedajo večje krvne ţile na mestu ali v bliţini mesta obsevanja; – načrtovan kirurški poseg v naslednjih 30 dneh; – sočasna očesna bolezen, za katero bo v naslednjih 30 dneh verjetno potreben pregled s špranjsko svetilko; – obstoječe zdravljenje z zdravilom, ki povzroča fotosensibilizacijo.
Some pulse oximeters may produce light of a wavelength close to that used for the photoactivation of Foscan.
Nekateri pulzni oksimetri oddajajo svetlobo z valovno dolţino blizu tiste, ki se uporablja za fotoaktivacijo zdravila Foscan.
Oximeters must be repositioned at least every 10-15 minutes to avoid the risk of local skin burns.
Oksimetre je potrebno prestavljati vsaj vsakih 10 do 15 minut, da se izognemo tveganju za lokalne opekline na koţi.
For 6 months following Foscan treatment avoid prolonged direct sunlight exposure of the injection site arm.
6 mesecev po zdravljenju z zdravilom Foscan mesto injiciranja zdravila na roki zaščitite pred dolgotrajno neposredno izpostavljenostjo sončni svetlobi.
Unplanned or emergency surgical procedures where Foscan has been administered within the previous 30 days must be undertaken only if absolutely necessary and the potential benefits outweigh the risk to the patient.
Nenačrtovani ali nujni kirurški posegi v primerih, kjer je bilo v preteklih 30 dneh injicirano zdravilo Foscan, naj se izvajajo le, če je to absolutno potrebno in če moţne koristi odtehtajo tveganje za bolnika.
Precautions must be taken to avoid exposure of skin and eyes to direct sunlight or bright indoor light during the first 15 days after injection.
Uporabljeni morajo biti vsi varnostni ukrepi, da koţa ali oči v prvih 15 dneh po injiciranju niso izpostavljeni neposredni sončni svetlobi ali močni svetlobi v notranjih prostorih.
Skin photosensitivity reactions are caused by visible light; therefore ultraviolet sunscreens provide no protection.
Fotosenzitivnostne reakcije na koţi povzroči vidna svetloba; zato kreme za sončenje z UV zaščitnimi faktorji ne nudijo nobene zaščite.
It is important that patients are re-introduced to normal light gradually.
Pomembno je, da se bolniki postopoma ponovno privajajo na normalno svetlobo.
Clinicians must counsel patients to observe the following precautions that are provided in the Package Leaflet.
Klinični zdravniki morajo bolnikom priporočiti, naj upoštevajo sledeča navodila, ki so zapisana v navodilu za uporabo:
3
3 Čas po injiciranju zdravila Foscan
Foscan Injection Day 1 (0-24 hours)
1. dan (0– 24 ur)
Stay indoors in a darkened room.
Bodite v zatemnjeni 60 W ali manj.
Keep the curtains drawn and use light bulbs of 60W or less.
sobi v hiši.
Avoid exposure to direct sunlight.
Zavese naj bodo zagrnjene, uporabljajte svetilke z močjo
Days 2-7
Ne izpostavljajte se neposredni sončni svetlobi.
Remember to avoid direct sunlight coming through the window or direct light from household appliances such as reading lamps.
Ne pozabite se izogibati Dnevi 2– 7 neposredni sončni svetlobi, ki prihaja skozi okno, ali neposredni svetlobi iz gospodinjskih aparatov, na primer bralnih luči.
If it is absolutely necessary to go outdoors during the hours of daylight, you must be careful to cover up all your skin including your face and hands and wear dark glasses.
Če se morate nujno odpraviti iz hiše v času dnevne svetlobe, si morate pazljivo pokriti vso koţo, vključno z obrazom in dlanmi, in nositi sončna očala.
Wide-brimmed hat: for head, neck, nose and ears.
Nositi morate sledeče vrste oblačil: klobuk s širokim robom: za glavo, vrat, nos in ušesa.
Sunglasses with side panels: for eyes and skin around eyes.
Sončna očala s stransko zaščito: za oči in koţo okrog oči.
Long sleeved top: for upper body/ arms.
Vrhnje oblačilo z dolgimi rokavi: za zgornji del telesa/ roke.
Long trousers: for lower body/ legs.
Dolge hlače: za spodnji del telesa/ noge.
Socks: for feet and ankles.
Nogavice: za stopala in gleţnje.
If you expose yourself to light by mistake, you may get a prickly or burning feeling on the skin.
Če se po nesreči izpostavite svetlobi, se lahko na koţi pojavi ščemeč ali ţareč občutek.
You may get eye pain or headache when lights are switched on.
Ob priţganih lučeh vas bodo morda bolele oči ali glava.
Days 8-14
Če boste imeli takšne teţave, nosite sončna očala.
Stay in shaded areas or go out when it is cloudy.
Zadrţujte se v senci ali Dnevi 8– 14 pojdite ven v oblačnem vremenu.
Start on Day 8 with 10-15 minutes outdoors.
Začnite 8. dan z 10– 15 minutami na prostem.
If you do not see any skin redness in the next 24 hours, you can gradually increase your time outdoors during the week.
Če se v naslednjih 24- ih urah ne pojavijo rdečine na koţi, lahko v tem tednu postopoma povečujete svoj čas na prostem.
Stay in the shade.
Zadrţujte se v senci.
You can then repeat the test.
Po teh 24- ih urah lahko ponovite preizkus.
On the first day after the skin test, you can stay in direct sunlight for 15 minutes.
Večina ljudi se bo lahko po 22. dnevu vrnila v normalni ritem ţivljenja.
You can increase your exposure by another 15 minutes each day i. e. second day 30 minutes, third day 45 minutes, fourth day 60 minutes and so on.
Prvi dan po koţnem preizkusu lahko ostanete na neposredni sončni svetlobi 15 minut Vsak dan lahko povečate izpostavljenost neposredni sončni svetlobi za 15 minut, to pomeni 30 minut drugi dan, 45 minut tretji dan, 60 minut četrti dan in tako naprej.
If at any time you notice a prickly or burning feeling or see skin reddening after exposure to sun, wait until this disappears before exposing your skin to light for this length of time again.
Če kadarkoli na koţi občutite ščemeč ali ţareč občutek ali opazite, da koţa po izpostavljenosti sončni svetlobi postaja rdeča, počakajte, da ti znaki izginejo, preden svojo koţo ponovno izpostavite sončni svetlobi za enako obdobje.